

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for treating a ~~disease condition~~ cancer of the central nervous system in a mammal, the method comprising:

(a) administering at least one vaccination of dendritic cells ("DC") to said mammal suffering from a cancer of the central nervous system; and

(b) after (a), administering a regimen of chemotherapy to said mammal, wherein said administering of at least one vaccination of DC occurs prior to administering said regimen of chemotherapy to said mammal, and wherein said regimen of chemotherapy includes the administration of at least one chemotherapeutic agent selected from the group consisting of temozolomide, procarbazine, carboplatin, vincristine, BCNU, CCNU, thalidomide, irinotecan, isotretinoin, imatinib, etoposide, and combinations thereof.

2. (Original) The method of claim 1, wherein said DC are primed ex vivo.

3. (Previously presented) The method of claim 1, wherein said DC are autologous, and wherein said DC are tumor antigen-presented DC.

4. (Withdrawn) The method of claim 1, wherein said DC are unprimed.

5. (Original) The method of claim 1, wherein administering said at least one vaccination further comprises administering at least three vaccinations of DC.

6. (Original) The method of claim 1, wherein each of said at least one vaccination of DC comprises from about 10^5 to about 10^7 DC.

7. (Original) The method of claim 1, wherein each of said at least one vaccination of DC comprises about 10×10^6 to about 40×10^6 DC.

8-9. (Canceled)

10. (Currently amended) The method of claim 1, wherein said ~~disease condition is a~~ cancer of the central nervous system is a glioma.

11. (Currently amended) The method of claim 1, wherein said ~~disease condition~~ cancer of the central nervous system is glioblastoma multiforme.

12-20. (Canceled)

21. (Withdrawn) A kit for use in the treatment of a disease condition, comprising: a quantity of dendritic cells ("DC"); a quantity of at least one chemotherapeutic agent; and instructions for use of said quantity of DC and said quantity of said at least one chemotherapeutic agent in the treatment of said disease condition.

22. (Withdrawn) The kit of claim 21, wherein said disease condition is a cancer of the central nervous system.

23. (Withdrawn) The kit of claim 21, wherein said disease condition is glioblastoma multiforme.

24. (Withdrawn) The kit of claim 21, further including at least one component for use in priming a quantity of DC ex vivo.

25. (New) The method of claim 2, wherein said cancer of the central nervous system is glioblastoma multiforme.

26. (New) The method of claim 25, wherein said mammal is a human.